Hiroki Kato1, Masayuki Matsuo2, Michio Ozeki3, Toshiyuki Fukao3. 1. Department of Radiology, Gifu University School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan. hkato@gifu-u.ac.jp. 2. Department of Radiology, Gifu University School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan. 3. Department of Pediatrics, Gifu University School of Medicine, Gifu, Japan.
Abstract
PURPOSE: To assess MR imaging findings of rebound adenoid hyperplasia after chemotherapy in pediatric patients with head and neck lymphoma. MATERIALS AND METHODS: Eight pediatric patients with head and neck lymphoma treated with chemotherapy alone or concurrent chemoradiotherapy were included. All patients underwent pre-therapeutic assessment and post-therapeutic follow-up by MR imaging. The maximum thickness of the adenoid was assessed on transverse T2-weighted images. Rebound adenoid hyperplasia was defined as more than half of the pre-therapeutic thickness after severe atrophy. RESULTS: The pre-therapeutic maximum thickness of the adenoid ranged from 10 to 18 mm (mean, 15 mm). In all patients, the thickness of the adenoid dramatically decreased (mean 1 mm) within 1 year after the cessation of chemotherapy. On follow-up MR imaging, rebound adenoid hyperplasia was observed in five patients (63 %). Re-atrophy following rebound adenoid hyperplasia was observed in two patients (25 %), and no re-atrophy was observed in three patients (37 %). Rebound adenoid hyperplasia was not observed in three patients (37 %) who were in their late teens, and who had been treated with concurrent chemoradiotherapy. CONCLUSION: Rebound adenoid hyperplasia was often observed after chemotherapy in pediatric patients with lymphoma. MR imaging was useful for the assessment of rebound adenoid hyperplasia.
PURPOSE: To assess MR imaging findings of rebound adenoid hyperplasia after chemotherapy in pediatric patients with head and neck lymphoma. MATERIALS AND METHODS: Eight pediatric patients with head and neck lymphoma treated with chemotherapy alone or concurrent chemoradiotherapy were included. All patients underwent pre-therapeutic assessment and post-therapeutic follow-up by MR imaging. The maximum thickness of the adenoid was assessed on transverse T2-weighted images. Rebound adenoid hyperplasia was defined as more than half of the pre-therapeutic thickness after severe atrophy. RESULTS: The pre-therapeutic maximum thickness of the adenoid ranged from 10 to 18 mm (mean, 15 mm). In all patients, the thickness of the adenoid dramatically decreased (mean 1 mm) within 1 year after the cessation of chemotherapy. On follow-up MR imaging, rebound adenoid hyperplasia was observed in five patients (63 %). Re-atrophy following rebound adenoid hyperplasia was observed in two patients (25 %), and no re-atrophy was observed in three patients (37 %). Rebound adenoid hyperplasia was not observed in three patients (37 %) who were in their late teens, and who had been treated with concurrent chemoradiotherapy. CONCLUSION: Rebound adenoid hyperplasia was often observed after chemotherapy in pediatric patients with lymphoma. MR imaging was useful for the assessment of rebound adenoid hyperplasia.
Authors: A D King; A C Vlantis; R K Y Tsang; T M K Gary; A K Y Au; C Y Chan; S Y Kok; W T Kwok; H K Lui; A T Ahuja Journal: AJNR Am J Neuroradiol Date: 2006 Jun-Jul Impact factor: 3.825
Authors: Ann D King; Alexander C Vlantis; Kunwar S S Bhatia; Benny C Y Zee; John K S Woo; Gary M K Tse; Anthony T C Chan; Anil T Ahuja Journal: Radiology Date: 2010-12-03 Impact factor: 11.105